Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. – 50. (Cancelled).

51. (Currently amended) A method for treating Autism in an individual~~, ADD (attention deficit disorder) or ADHD (attention deficit hyperactivity disorder) comprised of~~comprising:

administering a CARS (childhood autism rating scale) test to the individual prior to administration of digestive enzymes to determine the degree in which autism~~, ADD, or ADHD~~ symptoms are present;

determining if the individual has a fecal chymotrypsin level less than the normal fecal chymotrypsin level; ~~and~~

administering digestive enzymes to the individual if the determined fecal chymotrypsin level is less than the normal fecal chymotrypsin level; and

administering a CARS test to the individual after administration of the digestive enzymes to determine the degree in which autism symptoms are present post-administration of the digestive enzymes.

52. (Cancelled).

53. (Previously presented) The method of claim 51 wherein the digestive enzymes comprise a pancreatic enzyme.

54. (Previously presented) The method of claim 51, wherein the normal fecal chymotrypsin level is a level of fecal chymotrypsin associated with at least one other individual of the same approximate age that does not have the disorder.

55. (Previously presented) The method of claim 51 wherein the normal fecal chymotrypsin level is approximately 8.4 U/gm.

56. (Previously presented) The method of claim 51 wherein the step of administering digestive enzymes comprises administering an amount of digestive enzymes on a daily basis, wherein said amount is determined according to the age of the individual.

57. (Currently amended) The method of claim 56 wherein digestive enzymes are administered three to six times per day.

58. (New) The method of claim 51, further comprising determining the individual's fecal chymotrypsin level after administration of the digestive enzymes.

59. (New) The method of claim 51, wherein an overall CARS score from the CARS test for the individual decreases after administration of the digestive enzymes as compared to an overall CARS score from the CARS test for the individual prior to administration of the digestive enzymes.

60. (New) The method of claim 51, wherein the individual exhibits a decrease after administration of the digestive enzymes in one or more of the CARS test individual components selected from: visual response; verbal skills; touch/taste/smell; object use; non-verbal; emotion; intellect; relating; listening; imitation; body use; adaptation to change; activity level; and general impression.

61. (New) The method of claim 51, wherein the individual exhibits an amelioration after administration of the digestive enzymes in autistic symptomotology as evidenced by one or more of: increased eye contact; increased toilet training; increased speech; formed bowel movements; reduced hyperactivity; increased play with others; and reduced hand flapping.

62. (New) The method of claim 51, wherein the individual has a history of gastrointestinal (GI) dysfunction.

63. (New) The method of claim 51, wherein the individual has a self-limiting diet consisting primarily of carbohydrates.

64. (New) The method of claim 51, wherein the CARS test post-administration of the digestive enzymes is administered about three weeks after administration of the digestive enzymes.

65. (New) The method of claim 51, wherein the fecal chymotrypsin level is further determined about 6 months after administration of the digestive enzymes.

66. (New) The method of claim 51, wherein the individual's determined fecal chymotrypsin level is below 8.4 U/gm.

67. (New) The method of claim 51, wherein the individual's determined fecal chymotrypsin level is below 8.4 U/gm but above or equal to 4.2 U/gm.

68. (New) The method of claim 51, wherein the individual's determined fecal chymotrypsin level is below 4.2 U/gm.

69. (New) The method of claim 51, wherein the individual's fecal chymotrypsin level is determined using an enzymatic spectrophotometry method.

70. (New) The method of claim 69, wherein the enzymatic spectrophotometry method is performed at 30 °C.

71. (New) The method of claim 51, wherein the digestive enzymes comprise lipase, amylase, and protease enzymes.

72. (New) The method of claim 51, wherein the digestive enzymes comprise amylase, protease, lipase, sucrase, cellulase, and maltase enzymes.

73. (New) The method of claim 51, 71, or 72, wherein the digestive enzymes comprise chymotrypsin and trypsin enzymes.

74. (New) The method of claim 51, wherein the digestive enzymes are administered over a period of 6 months.

75. (New) The method of claim 51 wherein the normal fecal chymotrypsin level is about 8.4 U/gm, as determined at 30° C using an enzyme spectrophotometry method.

76. (New) The method of claims 66-68, wherein the fecal chymotrypsin level is determined at 30 °C using an enzyme spectrophotometry method.

77. (New) The method of claim 65, wherein the individual's fecal chymotrypsin level determined about 6 months post-administration of digestive enzymes increases relative to the individual's fecal chymotrypsin level determined prior to digestive enzyme administration.

78. (New) The method of claim 51, wherein the digestive enzymes comprise from 4000 to 20,000 USP of lipases; from 10,000 to 50,000 USP of proteases; and from 10,000-60,000 USP amylases.

79. (New) The method of claim 78, wherein the digestive enzymes comprise pancreatin from 2000 to 6000 USP.

80. (New) The method of claim 78, wherein the digestive enzymes comprise 2-5 mg of chymotrypsin and 60-100 mg of trypsin.

81. (New) The method of claim 51, further comprising comparing one or more of the results of the post-administration CARS test with one or more of the corresponding results of the pre-administration CARS test of the individual.

82. (New) A method for treating Autism in an individual comprising:

evaluating one or more autistic symptoms in the individual prior to administration of digestive enzymes;

determining if the individual has a fecal chymotrypsin level less than the normal fecal chymotrypsin level;

administering digestive enzymes to the individual if the determined fecal chymotrypsin level is less than the normal fecal chymotrypsin level, and

evaluating one or more autistic symptoms in the individual after administration of the digestive enzymes.

83. (New) The method of claim 82, wherein the digestive enzymes comprise a pancreatic enzyme.

84. (New) The method of claim 82, wherein the normal fecal chymotrypsin level is a level of fecal chymotrypsin associated with at least one other individual of the same approximate age that does not have the disorder.

85. (New) The method of claim 82, wherein the normal fecal chymotrypsin level is about 8.4 U/gm.

86. (New) The method of claim 82, wherein the step of administering digestive enzymes comprises administering an amount of digestive enzymes on a daily basis, wherein said amount is determined according to the age of the individual.

87. (New) The method of claim 86, wherein digestive enzymes are administered three to six times per day.

88. (New) The method of claim 82, further comprising determining the individual's fecal chymotrypsin level after administration of the digestive enzymes.

89. (New) The method of claim 82, wherein the individual exhibits an amelioration after administration of the digestive enzymes in autistic symptomotology as evidenced by one or more of: increased eye contact; increased toilet training; increased speech; formed bowel movements; reduced hyperactivity; increased play with others; and reduced hand flapping.

90. (New) The method of claim 82, wherein the individual has a history of gastrointestinal (GI) dysfunction.

91. (New) The method of claim 82, wherein the individual has a self-limiting diet consisting primarily of carbohydrates.

92. (New) The method of claim 82, wherein the fecal chymotrypsin level is further determined about 6 months after administration of the digestive enzymes.

93. (New) The method of claim 82, wherein the individual's determined fecal chymotrypsin level is below 8.4 U/gm.

94. (New) The method of claim 82, wherein the individual's determined fecal chymotrypsin level is below 8.4 U/gm but above or equal to 4.2 U/gm.

95. (New) The method of claim 82, wherein the individual's determined fecal chymotrypsin level is below 4.2 U/gm.

96. (New) The method of claim 82, wherein the digestive enzymes comprise one or more proteases.

97. (New) The method of claim 82, wherein the individual's fecal chymotrypsin level is determined using an enzymatic spectrophotometry method.

98. (New) The method of claim 97, wherein the enzymatic spectrophotometry method is performed at 30 °C.

99. (New) The method of claim 82, wherein the digestive enzymes comprise lipase, amylase, and protease enzymes.

100. (New) The method of claim 82, wherein the digestive enzymes comprise amylase, protease, lipase, sucrase, cellulase, and maltase enzymes.

101. (New) The method of claim 82, 99, or 100, wherein the digestive enzymes comprise chymotrypsin and trypsin enzymes.

102. (New) The method of claim 82, wherein the digestive enzymes are administered over a period of 6 months.

103. (New) The method of claim 82 wherein the normal fecal chymotrypsin level is about 8.4 U/gm, as determined at 30° C using an enzyme spectrophotometry method.

104. (New) The method of claims 93-95, wherein the fecal chymotrypsin level is determined at 30 °C using an enzyme spectrophotometry method.

105. (New) The method of claim 92, wherein the individual's fecal chymotrypsin level determined about 6 months post-administration of digestive enzymes increases relative to the individual's fecal chymotrypsin level determined prior to digestive enzyme administration.

106. (New) The method of claim 82, wherein the digestive enzymes comprise from 4000 to 20,000 USP of lipases; from 10,000 to 50,000 USP of proteases; and from 10,000-60,000 USP amylases.

107. (New) The method of claim 106, wherein the digestive enzymes comprise pancreatin from 2000 to 6000 USP.

108. (New) The method of claim 106, wherein the digestive enzymes comprise 2-5 mg of chymotrypsin and 60-100 mg of trypsin.

109. (New) A method for treating Autism in an individual comprising:

administering one or more diagnostic tests to determine the severity of one or more autistic symptoms in the individual prior to administration of the digestive enzymes;

determining if the individual has a fecal chymotrypsin level less than the normal fecal chymotrypsin level;

administering digestive enzymes to the individual if the determined fecal chymotrypsin level is less than the normal fecal chymotrypsin level;

administering one or more diagnostic tests to determine the severity of the one or more autistic symptoms in the individual after administration of the digestive enzymes.

110. (New) The method of claim 109, wherein the digestive enzymes comprise a pancreatic enzyme.

111. (New) The method of claim 109, wherein the normal fecal chymotrypsin level is a level of fecal chymotrypsin associated with at least one other individual of the same approximate age that does not have the disorder.

112. (New) The method of claim 109, wherein the normal fecal chymotrypsin level is about 8.4 U/gm.

113. (New) The method of claim 109, wherein the step of administering digestive enzymes comprises administering an amount of digestive enzymes on a daily basis, wherein said amount is determined according to the age of the individual.

114. (New) The method of claim 113, wherein digestive enzymes are administered three to six times per day.

115. (New) The method of claim 109, further comprising determining the individual's fecal chymotrypsin level after administration of the digestive enzymes.

116. (New) The method of claim 109, wherein the individual exhibits an amelioration after administration of the digestive enzymes in autistic symptomotology as evidenced by one or more of: increased eye contact; increased toilet training; increased speech; formed bowel movements; reduced hyperactivity; increased play with others; and reduced hand flapping.

117. (New) The method of claim 109, wherein the individual has a history of gastrointestinal (GI) dysfunction.

118. (New) The method of claim 109, wherein the individual has a self-limiting diet consisting primarily of carbohydrates.

119. (New) The method of claim 109, wherein the fecal chymotrypsin level is further determined about 6 months after administration of the digestive enzymes.

120. (New) The method of claim 109, wherein the individual's determined fecal chymotrypsin level is below 8.4 U/gm.

121. (New) The method of claim 109, wherein the individual's determined fecal chymotrypsin level is below 8.4 U/gm but above or equal to 4.2 U/gm.

122. (New) The method of claim 109, wherein the individual's determined fecal chymotrypsin level is below 4.2 U/gm.

123. (New) The method of claim 109, wherein the individual's fecal chymotrypsin level is determined using an enzymatic spectrophotometry method.

124. (New) The method of claim 123, wherein the enzymatic spectrophotometry method is performed at 30 °C.

125. (New) The method of claim 109, wherein the digestive enzymes comprise lipase, amylase, and protease enzymes.

126. (New) The method of claim 109, wherein the digestive enzymes comprise amylase, protease, lipase, sucrase, cellulase, and maltase enzymes.

127. (New) The method of claim 109, 125, or 126, wherein the digestive enzymes comprise chymotrypsin and trypsin enzymes.

128. (New) The method of claim 109, wherein the digestive enzymes are administered over a period of 6 months.

129. (New) The method of claim 109 wherein the normal fecal chymotrypsin level is about 8.4 U/gm, as determined at 30° C using an enzyme spectrophotometry method.

130. (New) The method of claims 120-122, wherein the fecal chymotrypsin level is determined at 30 °C using an enzyme spectrophotometry method.

131. (New) The method of claim 119, wherein the individual's fecal chymotrypsin level determined about 6 months post-administration of digestive enzymes increases relative to the individual's fecal chymotrypsin level determined prior to digestive enzyme administration.

132. (New) The method of claim 109, wherein the digestive enzymes comprise from 4000 to 20,000 USP of lipases; from 10,000 to 50,000 USP of proteases; and from 10,000-60,000 USP amylases.

133. (New) The method of claim 132, wherein the digestive enzymes comprise pancreatin from 2000 to 6000 USP.

134. (New) The method of claim 132, wherein the digestive enzymes comprise 2-5 mg of chymotrypsin and 60-100 mg of trypsin.

135. (New) A method of treating Autism in an autistic individual comprising:

administering digestive enzymes to the autistic individual.

136. (New) The method of claim 135, wherein a diagnosis of autism in the autistic individual is confirmed prior to administration of the digestive enzymes.

137. (New) The method of claim 135, wherein prior to administration of the digestive enzymes, one or more diagnostic tests to determine the severity of one or more autistic symptoms in the autistic individual are performed.

138. (New) The method of claim 135, wherein after administration of the digestive enzymes, one or more diagnostic tests to determine a reduction in the severity of one or more autistic symptoms in the autistic individual are performed.

139. (New) The method of claim 135, wherein prior to administration of the digestive enzymes, a fecal chymotrypsin level of the autistic individual is determined.

140. (New) The method of claim 139, wherein the determined fecal chymotrypsin level is compared to a normal fecal chymotrypsin value.

141. (New) The method of claim 140, wherein the determined fecal chymotrypsin level is below the normal fecal chymotrypsin value.

142. (New) The method of claim 135, wherein the digestive enzymes comprise one or more proteases.

143. (New) The method of claim 135, wherein the digestive enzymes comprise one or more lipases.

144. (New) The method of claim 135, wherein the digestive enzymes comprise one or more amylases.

145. (New) The method of claim 135, wherein the digestive enzymes comprise pancreatic enzymes.

146. (New) The method of claim 135, wherein the digestive enzymes comprise pancreatin.

147. (New) The method of claim 135, wherein the digestive enzymes comprise one or more of a cellulase, a sucrase, and a maltase.

148. (New) The method of claim 140, wherein the normal fecal chymotrypsin level is a level of fecal chymotrypsin associated with at least one other individual of the same approximate age that does not have the autism disorder.

149. (New) The method of claim 140, wherein the normal fecal chymotrypsin level is about 8.4 U/gm.

150. (New) The method of claim 135, wherein the step of administering digestive enzymes comprises administering an amount of digestive enzymes on a daily basis, wherein said amount is determined according to the age of the autistic individual.

151. (New) The method of claim 135, wherein the digestive enzymes are administered three to six times per day.

152. (New) The method of claim 139, further comprising determining the autistic individual's fecal chymotrypsin level after administration of the digestive enzymes.

153. (New) The method of claim 135, wherein the autistic individual exhibits an amelioration after administration of the digestive enzymes in autistic symptomotology as evidenced by one or more of: increased eye contact; increased toilet training; increased speech; formed bowel movements; reduced hyperactivity; increased play with others; and reduced hand flapping.

154. (New) The method of claim 135, wherein the autistic individual has a history of gastrointestinal (GI) dysfunction.

155. (New) The method of claim 135, wherein the autistic individual has a self-limiting diet consisting primarily of carbohydrates.

156. (New) The method of claim 139, wherein the fecal chymotrypsin level is further determined about 6 months after administration of the digestive enzymes.

157. (New) The method of claim 139, wherein the autistic individual's determined fecal chymotrypsin level is below 8.4 U/gm.

158. (New) The method of claim 139, wherein the individual's determined fecal chymotrypsin level is below 8.4 U/gm but above or equal to 4.2 U/gm.

159. (New) The method of claim 139, wherein the individual's determined fecal chymotrypsin level is below 4.2 U/gm.

160. (New) The method of claim 139, wherein the individual's fecal chymotrypsin level is determined using an enzymatic spectrophotometry method.

161. (New) The method of claim 160, wherein the enzymatic spectrophotometry method is performed at 30 °C.

162. (New) The method of claim 135, wherein the digestive enzymes comprise lipase, amylase, and protease enzymes.

163. (New) The method of claim 135, wherein the digestive enzymes comprise amylase, protease, lipase, sucrase, cellulase, and maltase enzymes.

164. (New) The method of claim 135, 162, or 163, wherein the digestive enzymes comprise chymotrypsin and trypsin enzymes.

165. (New) The method of claim 135, wherein the digestive enzymes are administered over a period of 6 months.

166. (New) The method of claim 139 wherein the normal fecal chymotrypsin level is about 8.4 U/gm, as determined at 30° C using an enzyme spectrophotometry method.

167. (New) The method of claims 157-159, wherein the fecal chymotrypsin level is determined at 30 °C using an enzyme spectrophotometry method.

168. (New) The method of claim 156, wherein the individual's fecal chymotrypsin level determined about 6 months post-administration of digestive enzymes increases relative to the individual's fecal chymotrypsin level determined prior to digestive enzyme administration.

169. (New) The method of claim 135, wherein the digestive enzymes comprise from 4000 to 20,000 USP of lipases; from 10,000 to 50,000 USP of proteases; and from 10,000-60,000 USP amylases.

170. (New) The method of claim 169, wherein the digestive enzymes comprise pancreatin from 2000 to 6000 USP.

171. (New) The method of claim 169, wherein the digestive enzymes comprise 2-5 mg of chymotrypsin and 60-100 mg of trypsin.